{"drugs":["Flecainide Acetate","Tambocor"],"mono":[{"id":"234185-s-0","title":"Generic Names","mono":"Flecainide Acetate"},{"id":"234185-s-1","title":"Dosing and Indications","sub":[{"id":"234185-s-1-4","title":"Adult Dosing","mono":"<ul><li>when transferring patients from another antiarrhythmic drug to flecainide, allow at least 2 to 4 plasma half-lives to elapse with  the initial drug before beginning flecainide therapy.  In patients  where withdrawal of a previous antiarrhythmic agent is likely to  produce life-threatening arrhythmias, hospitalization should be  considered.<\/li><li><b>Atrial fibrillation - Chemical cardioversion:<\/b> (pill-in-the-pocket) a single dose of flecainide 300 mg (body weight 70 kg or greater), and flecainide 200 mg (body weight less than 70 kg); prior to antiarrhythmic initiation, a beta blocker or nondihydropyridine calcium channel antagonist should be administered to prevent rapid AV conduction if atrial flutter occurs<\/li><li><b>Paroxysmal atrial fibrillation, Associated with disabling symptoms; Prophylaxis:<\/b> initial, 50 mg ORALLY every 12 hours<\/li><li><b>Paroxysmal atrial fibrillation, Associated with disabling symptoms; Prophylaxis:<\/b> titration, increase by 50 mg ORALLY twice daily at intervals of at least 4 days to a MAX daily dose of 300 mg<\/li><li><b>Paroxysmal atrial flutter, Associated with disabling symptoms; Prophylaxis:<\/b> initial, 50 mg ORALLY every 12 hours<\/li><li><b>Paroxysmal atrial flutter, Associated with disabling symptoms; Prophylaxis:<\/b> titration, increase by 50 mg ORALLY twice daily at intervals of at least 4 days to a MAX daily dose of 300 mg<\/li><li><b>Paroxysmal supraventricular tachycardia; Prophylaxis:<\/b> initial, 50 mg ORALLY every 12 hours<\/li><li><b>Paroxysmal supraventricular tachycardia; Prophylaxis:<\/b> titration, increase by 50 mg ORALLY twice daily at intervals of at least 4 days to a MAX daily dose of 300 mg<\/li><li><b>Ventricular arrhythmia, Life-threatening; Prophylaxis:<\/b> initial, 100 mg ORALLY every 12 hours<\/li><li><b>Ventricular arrhythmia, Life-threatening; Prophylaxis:<\/b> titration, increase by 50 mg ORALLY twice daily at intervals of at least 4 days to a MAX daily dose of 400 mg<\/li><\/ul>"},{"id":"234185-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy in fetus, infant, or child not established; initiate in hospital with rhythm monitoring and supervised by a cardiologist skilled in the treatment of arrhythmias in children<\/li><li><b>Paroxysmal atrial fibrillation, Associated with disabling symptoms; Prophylaxis:<\/b> (under6 months of age: initial, 50 mg\/m(2) ORALLY per day divided into 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><li><b>Paroxysmal atrial fibrillation, Associated with disabling symptoms; Prophylaxis:<\/b> over 6 months of age: initial, 100 mg\/m(2) ORALLY per day divided into 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><li><b>Paroxysmal atrial flutter, Associated with disabling symptoms; Prophylaxis:<\/b> less than 6 months of age: initial, 50 mg\/m(2) ORALLY per day divided in 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><li><b>Paroxysmal atrial flutter, Associated with disabling symptoms; Prophylaxis:<\/b> over 6 months of age: initial, 100 mg\/m(2) ORALLY per day divided in 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><li><b>Paroxysmal supraventricular tachycardia; Prophylaxis:<\/b> under 6 months of age: initial, 50 mg\/m(2) ORALLY per day divided into 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><li><b>Paroxysmal supraventricular tachycardia; Prophylaxis:<\/b> over 6 months of age: initial, 100 mg\/m(2) ORALLY per day divided into 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><li><b>Ventricular arrhythmia, Life-threatening; Prophylaxis:<\/b> less than 6 months of age, initial, 50 mg\/m(2) per day ORALLY divided in 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><li><b>Ventricular arrhythmia, Life-threatening; Prophylaxis:<\/b> over 6 months of age, initial, 100 mg\/m(2) ORALLY per day divided in 2 or 3 equally spaced doses up to a MAX dose of 200 mg\/m(2)\/day<\/li><\/ul>"},{"id":"234185-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>congestive heart failure:<\/b> initial dose, no more than 100 mg ORALLY every 12 hours<\/li><li><b>dialysis:<\/b> dosing adjustments do not appear necessary since only 1% of a dose is removed in the dialysate<\/li><li><b>liver disease:<\/b> dosage adjustments may be required (specific guidelines unavailable), monitor flecainide plasma levels<\/li><li><b>renal impairment:<\/b> CrCl greater than 35 mL\/min, initial dose: 100 mg ORALLY every 12 hours; monitor flecainide plasma levels<\/li><li><b>renal impairment:<\/b> CrCl 35 mL\/min or less, initial dose: 100 mg ORALLY once daily or 50 mg every 12 hours; monitor flecainide plasma levels<\/li><li><b>infants, change in dietary milk intake:<\/b> a dose reduction may be warranted when milk is removed from an infant's diet<\/li><\/ul>"},{"id":"234185-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Paroxysmal atrial fibrillation, Associated with disabling symptoms; Prophylaxis<\/li><li>Paroxysmal atrial flutter, Associated with disabling symptoms; Prophylaxis<\/li><li>Paroxysmal supraventricular tachycardia; Prophylaxis<\/li><li>Ventricular arrhythmia, Life-threatening; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Atrial fibrillation - Chemical cardioversion<\/li><li>Brugada syndrome; Diagnosis<\/li><li>Cardiac dysrhythmia - Myocardial infarction with complication<\/li><li>Fetal tachycardia<\/li><li>Supraventricular tachycardia<\/li><li>Ventricular arrhythmia, Benign<\/li><li>Wolff-Parkinson-White syndrome<\/li><\/ul>"}]},{"id":"234185-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Excessive mortality or nonfatal cardiac arrest rate was seen in patients with asymptomatic nonlife-threatening ventricular arrhythmias and myocardial infarction more than six days but less than two years previously who received flecainide compared with patients assigned to a carefully matched placebo in the Cardiac Arrhythmia Suppression Trial (CAST). It is prudent to consider the risks of Class IC agents (including flecainide), coupled with the lack of any evidence of improved survival, generally unacceptable in a patient without life-threatening ventricular arrhythmias, even if the patient is experiencing unpleasant, but not life-threatening, symptoms or signs.  Flecainide is not recommended for use in patients with chronic atrial fibrillation.  Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation\/flutter have included increased PVCs, VT, ventricular fibrillation (VF), and death.<br\/>"},{"id":"234185-s-3","title":"Contraindications\/Warnings","sub":[{"id":"234185-s-3-9","title":"Contraindications","mono":"<ul><li>cardiogenic shock<\/li><li>hypersensitivity to flecainide<\/li><li>right bundle branch block, with left hemiblock without pacemaker<\/li><li>second or third-degree atrioventricular block without pacemaker<\/li><\/ul>"},{"id":"234185-s-3-10","title":"Precautions","mono":"<ul><li>ventricular proarrhythmia, new-onset or worsening, particularly in patients with sustained ventricular tachycardia or serious underlying heart disease; initiation in hospital, careful titration, and monitoring recommended<\/li><li>cardiac arrest and death, in pediatrics; has been reported<\/li><li>chronic atrial fibrillation; use not recommended<\/li><li>congestive heart failure, particularly with history of cardiomyopathy, NYHA functional class III or IV heart failure, or low ejection fraction; increased risk of new onset or worsening congestive heart failure; dosage adjustment and monitoring plasma flecainide levels may be considered<\/li><li>congestive heart failure or myocardial dysfunction, history; use cautiously; lowering initial dose and monitoring recommended<\/li><li>myocardial infarction, recent; increased risk of mortality or cardiac arrest; do not use<\/li><li>electrolyte abnormalities (eg, hypo- or hyperkalemia); may alter effects of flecainide; correct prior to initiating drug<\/li><li>dietary milk intake changes in infants (eg, gastroenteritis or weaning); milk may inhibit flecainide absorption, a dose reduction may be warranted when milk is removed from an infant's diet; monitoring recommended<\/li><li>hepatic impairment, significant; assess risk\/benefit prior to administration; monitor plasma levels and titrate dose cautiously<\/li><li>permanent pacemaker or temporary pacing electrodes; flecainide may affect pacemaker thresholds; use with caution; monitoring recommended<\/li><li>poor thresholds or non-programmable pacemakers; do not initiate unless appropriate pacing rescue is available<\/li><li>renal impairment, severe (CrCl of 35 mL\/min\/1.73 m(2) or less); may require lower initial dose; monitoring recommended<\/li><li>sick sinus syndrome; may cause sinus bradycardia, sinus pause, or sinus arrest; use only with extreme caution<\/li><li>Torsade de Pointes-type arrhythmia has been reported<\/li><li>ventricular arrhythmia, less severe than sustained; use not recommended<\/li><\/ul>"},{"id":"234185-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Flecainide: C (FDA)<\/li><li>Flecainide: B3 (AUS)<\/li><\/ul>"},{"id":"234185-s-3-12","title":"Breast Feeding","mono":"<ul><li>Flecainide: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Flecainide: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},{"id":"234185-s-4","title":"Drug Interactions","sub":[{"id":"234185-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"234185-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Acecainide (theoretical)<\/li><li>Ajmaline (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (probable)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Arbutamine (probable)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Boceprevir (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorothiazide (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorthalidone (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darifenacin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Duloxetine (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrochlorothiazide (theoretical)<\/li><li>Hydroflumethiazide (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lidocaine (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metolazone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Peginterferon Alfa-2b (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Pirmenol (theoretical)<\/li><li>Polythiazide (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Prajmaline (theoretical)<\/li><li>Prilocaine (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sertraline (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trichlormethiazide (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"234185-s-4-15","title":"Moderate","mono":"<ul><li>Cimetidine (probable)<\/li><li>Digoxin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Propranolol (probable)<\/li><li>Verapamil (probable)<\/li><\/ul>"}]},{"id":"234185-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Palpitations (6.1%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (up to 10%)<\/li><li><b>Neurologic:<\/b>Dizziness (18.9% to 30% to 30%), Headache (4.5% to 9.6%)<\/li><li><b>Ophthalmic:<\/b>Blurred vision (10% to 38%), Photopsia (up to 30%)<\/li><li><b>Respiratory:<\/b>Dyspnea (up to 10.3%)<\/li><li><b>Other:<\/b>Fatigue (7.7%)<\/li><\/ul><b>Serious<\/b><br\/><b>Cardiovascular:<\/b>Cardiac arrest, Cardiac dysrhythmia, Cardiogenic shock, Disorder of pacing function, Electrocardiogram abnormal, Heart block, Heart failure, New onset or worsening (up to 25.7%), Prolonged QT interval, Sinus node dysfunction (1% to less than 3%), Syncope (1% to less than 3%), Torsades de pointes, Ventricular fibrillation, Ventricular tachycardia<br\/>"},{"id":"234185-s-6","title":"Drug Name Info","sub":{"0":{"id":"234185-s-6-17","title":"US Trade Names","mono":"Tambocor<br\/>"},"2":{"id":"234185-s-6-19","title":"Class","mono":"<ul><li>Amino Amide<\/li><li>Antiarrhythmic, Group IC<\/li><\/ul>"},"3":{"id":"234185-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"234185-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"234185-s-7","title":"Mechanism Of Action","mono":"Flecainide acetate is a class I C antiarrhythmic drug that possesses local anesthetic and electrophysiologic activity indicated for paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation\/flutter (PAF), and ventricular arrhythmias.<br\/>"},{"id":"234185-s-8","title":"Pharmacokinetics","sub":[{"id":"234185-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 3 h (1 h to 6 h)<\/li><li>Effect of food: none<\/li><li>Effect of food: (infant), milk inhibits absorption<\/li><\/ul>"},{"id":"234185-s-8-24","title":"Distribution","mono":"Protein binding: 40% <br\/>"},{"id":"234185-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic; P450 CYP2D6, extensive<\/li><li>Metabolite: meta-O-dealkylated flecainide<\/li><\/ul>"},{"id":"234185-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 5%<\/li><li>Renal: 30% unchanged (range 10% to 50%)<\/li><li>Renal: (renal impairment), reduced unchanged drug<\/li><li>Dialyzable: no (hemodialysis), about 1% unchanged<\/li><\/ul>"},{"id":"234185-s-8-27","title":"Elimination Half Life","mono":"<ul><li>20 h (range 12 h to 27 h)<\/li><li>Alkaline urine (pH 8 or higher): slow<\/li><li>Congestive heart failure: 19 h<\/li><li>At birth: 29 h<\/li><li>3 mo of age: 11 h to 12 h<\/li><li>1 y of age: 6 h<\/li><li>Hydropic infants: prolonged<\/li><li>1 y to 12 y: approximately 8 h<\/li><li>12 y to 15 y: approximately 11 h to 12 h<\/li><li>Elderly: slower than in younger subject<\/li><li>Renal impairment: prolonged<\/li><\/ul>"}]},{"id":"234185-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>Food or antacid do not affect absorption; however, milk, may inhibit absorption in infants <br\/>"},{"id":"234185-s-10","title":"Monitoring","mono":"<ul><li>ECG, heart rate, signs and symptoms of new or worsening cardiac failure<\/li><li>liver and renal function<\/li><li>adults: periodic trough plasma levels; 0.2-1 mcg\/mL<\/li><li>children: periodic trough plasma levels; 200-500 ng\/mL, up to 800 ng\/mL<\/li><\/ul>"},{"id":"234185-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 50 MG, 100 MG, 150 MG<br\/><\/li><li><b>Tambocor<\/b><br\/>Oral Tablet: 50 MG, 100 MG<br\/><\/li><\/ul>"},{"id":"234185-s-12","title":"Toxicology","sub":[{"id":"234185-s-12-31","title":"Clinical Effects","mono":"<b>FLECAINIDE <\/b><br\/>USES: Flecainide is an antidysrhythmic agent indicated for treatment of paroxysmal supraventricular dysrhythmia, paroxysmal atrial fibrillation\/flutter and life- threatening ventricular dysrhythmias. PHARMACOLOGY: Flecainide is a IC class antidysrhythmic which causes a decrease in intracardiac conduction for all parts of the heart, with the greatest effect in the His-Purkinje system. It acts by blocking fast sodium channels. Type IC agents slow cardiac conduction and decrease contractility. On an ECG this appears as markedly widened QRS complex, slightly widened QT interval, and PR prolongation from slowed conduction through the AV node. Some proarrhythmic effects may occur with therapeutic use. In overdose situations, these effects are exaggerated. TOXICOLOGY: In overdose situations, the above effects are exaggerated. EPIDEMIOLOGY: Overdose is rare, but life-threatening. MILD TO MODERATE TOXICITY: Dizziness, visual disturbances, headache, nausea, fatigue, palpitation, and chest pain. Visual hallucinations and dysarthria may occur at toxic serum concentrations. SEVERE TOXICITY: Seizures, CNS depression, hepatotoxicity, hypotension, ventricular tachydysrhythmias, severe bradycardia, variable degrees of atrioventricular block, marked prolongation of the QRS, QT, and T waves, cardiogenic shock, pulmonary edema, renal failure, metabolic acidosis, leukocytosis, hypokalemia, cardiac arrest. Fatalities have been reported as a consequence of rapid onset hypotension and ventricular dysrhythmias following severe overdoses. ADVERSE EFFECTS: COMMON: Dizziness, visual disturbances and dyspnea. Other symptoms occurring in 5% to 10% of patients include headache, nausea, fatigue, palpitation and chest pain.<br\/>"},{"id":"234185-s-12-32","title":"Treatment","mono":"<b>FLECAINIDE <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treat seizures with benzodiazepines. Manage mild hypotension with IV fluids. MANAGEMENT OF SEVERE TOXICITY: Treat ventricular dysrhythmias with sodium bicarbonate, correct electrolyte abnormalities, and perform cardioversion for unstable rhythms. Consider intravenous lipid therapy early for patients with ventricular dysrhythmias or hypotension. Antidysrhythmic drugs are generally not effective, and some (procainamide, disopyramide, encainide, sotalol, propafenone) should be avoided. Consider extracorporeal support (cardiopulmonary bypass, extracorporeal membrane oxygenation, aortic balloon pump) early in unstable patients. Treat torsades de pointes with magnesium and overdrive pacing. Intubate patients with hemodynamic instability, dysrhythmias or CNS depression. Treat hypotension initially with IV fluids, then vasopressors if necessary. Treat seizures with benzodiazepines, add propofol or barbiturates if seizures persist.<\/li><li>Decontamination: PREHOSPITAL: Prehospital gastrointestinal decontamination is not recommended because of potential for CNS depression, seizures, and cardiovascular instability. HOSPITAL: Consider gastric lavage after ingestion of a potentially life-threatening amount of poison if it can be performed soon after ingestion (generally within 1 hour) and the airway is protected. Consider activated charcoal in patients with a potentially toxic ingestion who are awake and able to protect their airway. Because of the potential for abrupt onset of hemodynamic instability or seizures, consider intubating the patient to protect the airway first. Most effective when administered within one hour of ingestion.<\/li><li>Airway management: Endotracheal intubation should be performed in patients with excessive drowsiness, seizures, hemodynamic instability or the inability to protect their own airway.<\/li><li>Ventricular arrhythmia: Initial treatment with sodium bicarbonate boluses to decrease the amount of sodium channel blockade. Frequent ECGs and continuous cardiac monitoring. Monitor arterial blood gases to target pH 7.45 to 7.55. Ventricular tachycardia induced by flecainide has been difficult to treat and refractory to conventional antidysrhythmic drug therapy, cardioversion, and ventricular pacing. Minimize aggravating conditions for dysrhythmias (eg, electrolyte abnormalities, hypoxia). Consider intravenous lipid therapy for patients with ventricular dysrhythmias or hypotension. Avoid drugs with similar sodium channel blocking effects. Antidysrhythmics are rarely effective. Consider overdrive transvenous pacing. Avoid procainamide and disopyramide as they may worsen flecainide-induced dysrhythmias. Institute cardiopulmonary bypass, extracorporeal membrane oxygenation, or intra-aortic balloon pump early for patients with persistent hemodynamic instability. The goal is to support the patient hemodynamically while the flecainide is metabolized.<\/li><li>Torsades de pointes: Hemodynamically unstable patients require electrical cardioversion. Treat stable patients with magnesium and\/or atrial overdrive pacing. Correct electrolyte abnormalities (ie, hypomagnesemia, hypokalemia, hypocalcemia) and hypoxia. Avoid class Ia (eg, quinidine, disopyramide, procainamide), class IC (eg, flecainide, encainide, propafenone) and most class III antidysrhythmics (eg, N-acetylprocainamide, sotalol).<\/li><li>Fat emulsion: Patients who develop significant cardiovascular toxicity should be treated with intravenous lipids. Administer 1.5 mL\/kg of 20% lipid emulsion over 2 to 3 minutes as an IV bolus, followed by an infusion of 0.25 mL\/kg\/min. If possible, discontinue after 30 to 60 minutes. Longer periods of lipid therapy should be considered if the patient's hemodynamic stability is dependent on continued lipid infusion.<\/li><li>Acute lung injury: Maintain ventilation and oxygenation and evaluate with frequent arterial blood gas or pulse oximetry. Early use of positive end expiratory pressure (PEEP) and mechanical ventilation may be needed.<\/li><li>Seizure: Administer IV benzodiazepines; barbiturates or propofol may be needed if seizures persist or recur.<\/li><li>Hypotensive episode: Administer isotonic IV fluids for hypotension. Consider vasopressors for persistent hypotension.<\/li><li>Monitoring of patient: Monitor vital signs frequently, obtain serial ECGs, and institute continuous cardiac monitoring. Monitor serum electrolytes and acid\/base balance. Monitor for seizures and CNS depression following substantial overdoses. While flecainide concentrations can be measured, they are not rapidly available and not useful to guide overdose treatment. A therapeutic level is estimated at 0.2 to 1 mcg\/mL; levels greater than 1.5 mcg\/mL may be considered toxic.<\/li><li>Enhanced elimination procedure: Methods to enhance elimination such as hemodialysis and hemoperfusion are ineffective due to the drug's large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: There is no role for home management of flecainide overdose. OBSERVATION CRITERIA: Patients with overdose (including children with inadvertent exposures) should be referred to a healthcare facility for evaluation and treatment. Because of the potential for abrupt instability, patients should be transferred by ambulance. Patients should be observed for at least 6 hours after exposure. ADMISSION CRITERIA: All patients who are symptomatic should be admitted to an intensive care setting for at least 24 hours. CONSULT CRITERIA: Consult a medical toxicologist for assistance with medical management. Consult an intensivist, cardiologist, or cardiothoracic surgeon to institute cardiopulmonary bypass, extracorporeal membrane oxygenation, or aortic balloon pump in patients with hemodynamic instability.<\/li><\/ul>"},{"id":"234185-s-12-33","title":"Range of Toxicity","mono":"<b>FLECAINIDE <\/b><br\/>TOXICITY: An ingestion of 1200 mg was lethal in an adult and 1500 mg has caused life threatening toxicity. Overdoses of up to 9 g have been survived with intensive supportive care; peak plasma levels up to 20.5 mcg\/mL have been survived. Adverse effects related to flecainide are usually seen at serum concentrations above 700 mcg\/L. THERAPEUTIC DOSE: ADULTS: ORAL: doses range from 50 mg twice daily to 400 mg\/day depending on indication. Intravenous flecainide is not available in the United States. CHILDREN: 6 MONTHS OF AGE AND OLDER: 100 mg\/m(2)\/day orally in 2 or 3 divided doses. MAXIMUM DOSE: 200 mg\/m(2)\/day. LESS THAN 6 MONTHS OF AGE: 50 mg\/m(2)\/day orally in 2 or 3 divided doses. MAXIMUM DOSE: 200 mg\/m(2)\/day. <br\/>"}]},{"id":"234185-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness and blurred vision.<\/li><li>Drug may cause dyspnea, headache, nausea, and fatigue.<\/li><li>Instruct patient to report signs\/symptoms of new or worsening cardiac failure, arrhythmias, or chest pain.<\/li><li>Advise caregiver of infant to report change in dietary milk intake as dose adjustments may be needed.<\/li><\/ul>"}]}